Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial
Circulation: Cardiovascular Interventions · 2024
DOI: 10.1161/circinterventions.123.013596 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Circulation: Cardiovascular Interventions, 2024. Verfasst von Alexander C Fanaroff und 8 weiteren Autor:innen. Beteiligte Einrichtung: Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute for Health Economics, and Division of Cardiovascular M…. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Anticoagulants, Atrial Fibrillation, Dual Anti-Platelet Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In the AUGUSTUS trial (An Open-Label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), the combination of dual antiplatelet therapy plus oral anticoagulation increased the risk of bleeding without reducing ischemic events compared with a P2Y12 inhibitor plus oral anticoagulation among patients with atrial fibrillation and acute coronary syndrome or elective percutaneous coronary intervention. However, AUGUSTUS enrolled patients up to 14 days after acute coronary syndrome or percutaneous coronary intervention, and there may be a benefit to dual antiplatelet therapy plus oral anticoagulation early after an ischemic event. METHODS: In this secondary analysis of AUGUSTUS, we divided patients into groups based on whether they were enrolled
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute for Health Economics, and Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia (A.C.F.).
- Duke Clinical Research Institute (D.M.W., C.B.G., J.H.A., R.D.L.), Duke University, Durham, NC.
- Division of Cardiovascular Medicine (C.B.G., J.H.A., R.D.L.), Duke University, Durham, NC.
- Canadian VIGOUR Centre, University of Alberta, Edmonton (S.G.G.).
- Terrence Donnelly Heart Centre, St. Michael's Hospital, University of Toronto, ON (S.G.G.).
- Bristol Myers Squibb, Princeton, NJ (R.S.A.).
ORCID-Profile: Alexander C Fanaroff, Christopher B Granger, Shaun G Goodman, Ronald S Aronson, Stephan Windecker, Roxana Mehran, John H Alexander, Renato D Lopes
Zitieren
APA
Fanaroff, A. C., Wojdyla, D. M., Granger, C. B., Goodman, S. G., Aronson, R. S., Windecker, S., Mehran, R., Alexander, J. H., & Lopes, R. D. (2024). Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.123.013596
Vancouver
Fanaroff AC, Wojdyla DM, Granger CB, Goodman SG, Aronson RS, Windecker S, et al. Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial. Circulation: Cardiovascular Interventions. 2024. doi:10.1161/circinterventions.123.013596
BibTeX
@article{Fanaroff2024,
author = {Fanaroff, Alexander C and Wojdyla, Daniel M and Granger, Christopher B and Goodman, Shaun G and Aronson, Ronald S and Windecker, Stephan and Mehran, Roxana and Alexander, John H and Lopes, Renato D},
title = {Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial},
journal = {Circulation: Cardiovascular Interventions},
year = {2024},
doi = {10.1161/circinterventions.123.013596}
}
EUVIMED